A doctor who researches cancer treatments hopes his fellow Bermudians will turn out when he battles to win funds for a clinical trial.
Sheldon Holder is one of four finalists in a virtual pitch compet.
Of St. Paul, MN passed away peacefully on July 16, 2022. He is survived by his wife Arlene; stepdaughters, Havi Goodman of Baltimore, MD, Barbara Goodman of Chicago, IL; beloved and only grandchild, Ravi Goodman, of Chicago; and sister, Mary Margaret Alm and her husband, Darrell Scott Russell of Asheville, NC. He was preceded in death by his parents, Arthur Gilman Alm and Mary (May) Curran Alm and brother, Michael. Tom died after a valiant struggle with blood cancer, missing his long-anticipated 80th birthday by only a few weeks. Born on August 6, 1942 in Fargo, ND, Tom graduated from North Dakota State University and entered the U.S. Army as a Second Lieutenant. After two years of active service, including a year in Vietnam, he moved to St. Paul, working for and retiring from the Minnesota Department of Employment and Economic Development. In 1990, at a performance of the Saint Paul Chamber Orchestra, he met Arlene Davis Goodman, and they married in 1992. Arlene brought Tom a life of
Research is an integral part of Emory, from the sciences to the humanities. Read a sample of recent grant awards across campus along with newly published research findings.
ALISO VIEJO, Calif. (BUSINESS WIRE) Apr 29, 2021
The international rare disease patient advocacy organization, Global Genes, is pleased to announce the 6th Annual RARE Drug Development Symposium (RDDS) in partnership with the Orphan Disease Center of the University of Pennsylvania. The June 9-11 virtual event will connect and educate hundreds of advocates, clinicians, and academic and industry researchers to explore the latest science, opportunities, and challenges to the advancement of therapies for more than 7,000 rare diseases.
New to this year s event is an optional preconference workshop targeted to attendees who are in the earlier stages of their research efforts or careers and looking to build knowledge in core competencies that will be expanded upon in the main RDDS program. The main program will address the current landscape of rare drug development and allow attendees to interact with subject matter experts and other rare disease stakeholders to help them better understa